
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Supplements and Featured Publications
over 27 years ago
Participating Facultyover 27 years ago
Clinical Aspects of Combination Therapyover 27 years ago
Cost Effectiveness of Combination Therapyover 27 years ago
The Role of Combination Therapy in Achieving Blood Pressure Controlover 27 years ago
Selected Abstractsover 27 years ago
CME Quizover 27 years ago
Bibliography




